Cited by 66Natural Antidiabetic Agents StudiesAdvanced Drug Delivery SystemsPharmacology and Nanomedicine Research

Development of polyherbal antidiabetic formulation encapsulated in the phospholipids vesicle system

Open access
Kalia, AjudhiaNath, Gauttam, VinodKumar·2013·Journal of Advanced Pharmaceutical Technology amp Research

Abstract

Multifactorial metabolic diseases, for instance diabetes develop several complications like hyperlipidemia, hepatic toxicity, immunodeficiency etc., Hence, instead of mono-drug therapy the management of the disease requires the combination of herbs. Marketed herbal drugs comprise of irrational combinations, which makes their quality control more difficult. Phytoconstituents, despite having excellent bioactivity in vitro demonstrate less or no in vivo actions due to their poor lipid solubility, resulting in high therapeutic dose regimen; phospholipids encapsulation can overcome this problem. Hence, present study was designed to develop a phospholipids encapsulated polyherbal anti-diabetic formulation. In the present study, polyherbal formulation comprises of lyophilized hydro-alcoholic (50% v/v) extracts of Momordica charantia, Trigonella foenum-graecum and Withania somnifera 2:2:1, respectively, named HA, optimized based on oral glucose tolerance test model in normal Wistar rats. The optimized formulation (HA) entrapped in the phosphatidylcholine and cholesterol (8:2) vesicle system is named HA lipids (HAL). The vesicles were characterized for shape, morphology, entrapment efficiency, polar-dispersity index and release profile in the gastric pH. The antidiabetic potential of HA, marketed polyherbal formulation (D-fit) and HAL was compared in streptozotocin-induced diabetic rat model of 21 days study. The parameters evaluated were behavioral changes, body weight, serum glucose level, lipid profile and oxidative stress. The antidiabetic potential of HA (1000 mg/kg) was at par with the D-fit (1000 mg/kg). However, the potential was enhanced by phospholipids encapsulation; as HAL (500 mg/kg) has shown more significant (P < 0.05) potential in comparison to HA (1000 mg/kg) and at par with metformin (500 mg/kg).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4103/2231-4040.111527

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. [5]Kennedy J Cabral J Recovery processes for biological materials 1992 Chichester Wiley
  2. [6]Kumar BD Mitra A Manjunatha M In vitro and in vivo studies of antidiabetic Indian medicinal plants: A review J Herbal Med Toxicol 2009 3 9 14
  3. [23]Roeschlau P Bernt E Gruber W Enzymatic determination of total cholesterol in serum J Clin Chem Biochem 1974 12 403 7 4428856

Cited by

Sorted by citations

Authors
Kalia, A., & Gauttam, V.
Venue
Journal of Advanced Pharmaceutical Technology amp Research
Published
2013
Volume
4
Issue
2
Pages
108
ISSN
  • 0976-2094 (ISSN-L)
  • 2231-4040
OpenAlex
W2111284394
Cited by
66
References
2
Citations by year
2026: 6 · 2025: 8 · 2024: 9 · 2023: 11 · 2022: 4 · 2021: 5 · 2020: 11 · 2019: 2 · 2018: 3 · 2017: 3 · 2016: 1 · 2015: 2 · 2014: 1
FWCI
1.05
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • Journal of Advanced Pharmaceutical Technology amp Research (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Pharmacology and Nanomedicine Research
Keywords
polyherbal formulation, antidiabetic herbal medicine, phospholipid vesicles, phosphatidylcholine, cholesterol, Momordica charantia, fenugreek, Withania somnifera, encapsulation efficiency, oral glucose tolerance, streptozotocin-induced diabetes, oxidative stress, lipid profile, serum glucose, metformin comparison

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review